Methotrexate Accord Healthcare

Methotrexate, the active ingredient in Methotrexate Accord Healthcare, is an antimetabolite (folate antagonist) presented as a sterile injectable solution for intra‑arterial, intramuscular, or intravenous use. It is employed to treat certain cancers, autoimmune disorders and ectopic pregnancy in adult patients. GNH USA supplies Methotrexate Accord Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Methotrexate is used across several disease families, primarily as an antineoplastic and immunosuppressive agent. - Rheumatoid arthritis: reduces inflammatory activity and slows joint damage in adult patients. - Psoriasis: limits skin cell proliferation and improves plaque lesions. - Acute lymphoblastic leukemia: interferes with malignant cell replication to achieve remission. - Non‑Hodgkin lymphoma: impedes tumor growth as part of combination chemotherapy. - Ectopic pregnancy: halts trophoblastic tissue development to allow non‑surgical resolution.

Methotrexate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea or vomiting. - Fatigue or general weakness. - Oral mucosal ulceration (mouth sores). - Transient elevation of liver enzymes. - Mild alopecia (hair thinning). - Decreased white blood cell count.

Serious or Rare Side Effects: - Severe hepatic toxicity or fibrosis. - Pulmonary fibrosis or interstitial pneumonitis. - Life‑threatening bone marrow suppression leading to pancytopenia. - Acute renal failure. - Severe cutaneous reactions such as Stevens‑Johnson syndrome. - Opportunistic infections due to profound immunosuppression.

Before initiating therapy, clinicians should evaluate baseline organ function and counsel patients on potential risks. - Monitor liver function: obtain baseline and periodic liver enzyme tests. - Monitor blood counts: perform regular complete blood counts to detect cytopenias. - Assess renal function: adjust dosing in patients with impaired clearance. - Avoid use in pregnancy: methotrexate is teratogenic and contraindicated. - Review concomitant NSAID use: NSAIDs can increase methotrexate toxicity. - Store at ambient temperature: keep in original container, protect from moisture and light.

Methotrexate interacts with several drug classes; awareness helps prevent toxicity.

Major Interactions (Avoid): - Concurrent folate antagonists (e.g., trimethoprim) – may amplify myelosuppression. - High‑dose NSAIDs – increase serum methotrexate levels and renal toxicity. - Live vaccines – risk of severe infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Azathioprine or cyclophosphamide – additive bone marrow suppression. - Proton pump inhibitors – may reduce renal clearance of methotrexate. - Oral contraceptives – may alter hormone levels; monitor efficacy. - Allopurinol – can increase methotrexate toxicity; adjust dose if needed.